Andy <span>M.</span> Trotti
Researcher

Andy M. Trotti

Academic Rank: Senior Member

Overview

As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, the adverse effects of cancer treatment, and HPV (Human Papilloma Virus) - related oral cancers. Dr. Trotti is currently leading the largest international trial testing a reduced toxicity agent (cetuximab) in HPV-related oral cancers. This study has enrolled 900 patients at 85 centers and initial results are expected in 2017. He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 25 years. 

Discipline

    • Radiation Oncology
    • Chemical Biology and Molecular Medicine Program
    • Melanoma Research Center of Excellence

Education & Training

    • University of Florida, MD
    • University of Alabama at Birmingham, Resident - Radiation Oncology
Research

As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, the adverse effects of cancer treatment, and HPV (Human Papilloma Virus) - related oral cancers. Dr. Trotti is currently leading the largest international trial testing a reduced toxicity agent (cetuximab) in HPV-related oral cancers. This study has enrolled 900 patients at 85 centers and initial results are expected in 2017. He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 25 years. Dr. Trotti was recognized as Clinical Educator of the Year at Moffitt in 2010. He has also delivered several honorary lectures including the keynote address at the American Head and Neck Society and the Wharton Lecture at Princess Margaret Hospital. Under his leadership, Moffitt became a member of the National Cancer Institute-sponsored Radiation Therapy Oncology Group (RTOG) in 1990 and continues today as one of a select group of active full members. Dr. Trotti serves as institutional principal investigator for RTOG studies. Dr. Trotti is co-chair of the RTOG Head and Neck Committee. Under his guidance, several of his radiation oncology colleagues at Moffitt have participated in leadership roles within RTOG, including the Quality of Life Committee, Outcomes Committee, Special Populations Committee, and Research Associates Committee. As part of the effort to measure outcomes, Darlene Johnson, MBA and Dr. Trotti developed and validated a radiation-specific quality of life tool used in two national RTOG trials. Dr. Trotti and colleague Dr. Javier Torres-Roca were awarded a pilot grant to study genomic predictors of radiosensitivity in RTOG populations. Dr. Trotti has served as co-chair of the Health Services Research (HSR) Committee for both the American Society of Therapeutic Radiology and Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO). Dr. Trotti has a unique area of expertise: the recognition, reporting, prevention, and management of the adverse effects of cancer treatment. Dr. Trotti assisted the NCI in creating the current NCI dictionary for adverse events (CTCAE). This document has become the international standard language for toxicity reporting. He has also led pivotal trials testing iseganan and lisofylline in mucositis. Dr. Trotti and colleagues were awarded federal grants to develop electronic methods of grading and reporting toxicity in clinical trials (Safety Profiler).

Publications

  • Ringash J, Fisher R, Peters L, Trotti A, O'Sullivan B, Corry J, Kenny L, Van Den Bogaert W, Wratten C, Rischin D. Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys. 2017 Mar;97(4):678-686. Pubmedid: 27209505.
  • Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiatio. Int J Radiat Oncol Biol Phys. 2017 Mar;97(4):687-699. Pubmedid: 27727066. Pmcid: PMC5303682.
  • Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Garden AS, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017 Jul. Pubmedid: 28757375.
  • Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. Geriatr Oncol. 2017 Jan;8(1):50-55. Pubmedid: 27720129.
  • Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck. 2017 Jan;39(1):48-55. Pubmedid: 27300153.
  • Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Aug. Pubmedid: 28777690.
  • Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr;15(4):473-482. Pubmedid: 28404758.
  • Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr;3(4):483-491. Pubmedid: 28006059. Pmcid: PMC5470422.
  • Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, Harrison LB, Lu C, Moeller BJ, Quon H, Rocco JW, Sturgis EM, Tishler RB, Trotti A, Waldron J, Eisbruch A. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017 Apr;7(4):246-253. Pubmedid: 28428019.
  • Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Vargo J, Heron DE, Higgins KA, Beitler JJ, Yao M, Machtay M, Siddiqui F, Trotti A, Lee N, Koyfman S. Multi-Institution Analysis of Intensity Modulated Radiation Therapy-Based Reirradiation for Head and Neck Cancer: Prognostic Factors and Recursive Partitioning Analysis for Overall Survival. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):S115. Pubmedid: 27675561.
  • Naghavi AO, Echevarria M, Strom T, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Race Is Associated With Poor Outcomes in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E407. Pubmedid: 27674609.
  • Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016 Oct;23(11):3572-3578. Pubmedid: 27251134.
  • Awan MJ, Zakem SJ, Ward MC, Machtay M, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Dault J, Higgins KA, Beitler JJ, Siddiqui F, Trotti A, Lee N, Koyfman S, Heron DE, Yao M. Reirradiation Outcomes After Upfront Larynx Preservation or Total Laryngectomy: A Multi-institutional Analysis. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E376. Pubmedid: 27674522.
  • Naghavi AO, Strom T, Abuodeh YA, Frakes JM, Ahmed KA, Harrison LB, Trotti A, Caudell JJ. Risk Factors for Recurrence in Human Papillomavirus-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E372-E373. Pubmedid: 27674513.
  • Naghavi AO, Strom T, Abuodeh YA, Echevarria M, Russell J, Kish JA, Balducci L, Trotti A, Harrison LB, Caudell JJ. Concurrent Chemotherapy in Elderly Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E362. Pubmedid: 27674484.
  • Parekh A, Strom T, Naghavi AO, Caudell JJ, Zager JS, Messina JL, Torres-Roca JF, Sondak VK, Trotti A, Harrison LB. Does Regional Radiation Therapy Impact Outcome for High-Risk, Node-Positive Cutaneous Melanoma?. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):S157. Pubmedid: 27675666.
  • Mifsud MJ, Tanvetyanon T, Mccaffrey JC, Otto KJ, Padhya TA, Kish J, Trotti AM, Harrison LB, Caudell JJ. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. Head Neck. 2016 Nov;38(11):1628-1633. Pubmedid: 27098984.
  • Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck. 2016 Jun;38(6):863-870. Pubmedid: 26340707.
  • Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang QE, Le QT, Holsinger FC. Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016 Jul. Pubmedid: 27419843. Pmcid: PMC5237619.
  • Naghavi AO, Strom TJ, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016 Jul;23(3):197-207. Pubmedid: 27556659.
  • Mifsud MJ, Burton JN, Trotti AM, Padhya TA. Multidisciplinary Management of Salivary Gland Cancers. Cancer Control. 2016 Jul;23(3):242-248. Pubmedid: 27556664.
  • Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan;126(2):309-316. Pubmedid: 26508094. Pmcid: PMC4720526.
  • Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016 Feb;122(4):634-641. Pubmedid: 26565997.
  • Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016 Dec;45:18-25. Pubmedid: 27664388.
  • Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys. 2016 Aug;95(5):1346-1354. Pubmedid: 27212198. Pmcid: PMC5199017.
  • Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016 Aug. Pubmedid: 27479362.
  • Frakes JM, Strom TJ, Naghavi AO, Trotti A, Rao NG, McCaffrey JC, Otto KJ, Padhya T, Caudell JJ. Outcomes of mucosal melanoma of the head and neck. J Med Imaging Radiat Oncol. 2016 Apr;60(2):268-273. Pubmedid: 26597431.
  • Forastiere AA, Weber RS, Trotti A. Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes. J Clin Oncol. 2015 Oct;33(29):3262-3268. Pubmedid: 26351339. Pmcid: PMC5320920.
  • Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar AK, Garden AS, Soulieres D, Trotti A, Avizonis VN, Ridge JA, Harris J, Le QT, Gillison M. Reply to B. O'Sullivan et Al. J Clin Oncol. 2015 May;33(15):1708-1709. Pubmedid: 25823732.
  • Schwartz DL, Harris J, Yao M, Rosenthal DI, Opanowski A, Levering A, Ang KK, Trotti AM, Garden AS, Jones CU, Harari P, Foote R, Holland J, Zhang Q, Le QT. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys. 2015 Mar;91(4):721-729. Pubmedid: 25752384. Pmcid: PMC4672942.
  • Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015 Jun;37(6):840-845. Pubmedid: 24623654.
  • Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015 Jul;51(7):704-708. Pubmedid: 25936651.
  • Yom SS, Gillison ML, Trotti AM. Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder. Int J Radiat Oncol Biol Phys. 2015 Dec;93(5):986-988. Pubmedid: 26581136.
  • Axelrod RS, Sherman E, Garden A, Nguyen-Tan PF, Trotti A, Yom SS, Zhang Q. Reply to D. Adkins et al. J Clin Oncol. 2015 Apr;33(10):1224-1225. Pubmedid: 25713438.
  • Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep;32(27):2940-2950. Pubmedid: 25513450.
  • Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep;32(27):2940-2950. Pubmedid: 25154822. Pmcid: PMC4162493.
  • Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014 Oct;32(30):3365-3373. Pubmedid: 24958820. Pmcid: PMC4195851.
  • Trotti A, Machtay M. RTOG 9003: legacies of a landmark trial. Int J Radiat Oncol Biol Phys. 2014 Oct;90(2):253-254. Pubmedid: 25304786.
  • Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, Marzban SS, Messina JL, Trotti AM, Sondak VK, Rao NG. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014 May;120(9):1369-1378. Pubmedid: 24142775. Pmcid: PMC4515972.
  • Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014 May;89(1):13-20. Pubmedid: 24613816. Pmcid: PMC4664465.
  • Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol. 2014 Mar;3(3):229-233. Pubmedid: 24674369.
  • Javedan K, Feygelman V, Zhang RR, Moros EG, Correa CR, Trotti A, Li W, Zhang GG. Monte Carlo comparison of superficial dose between flattening filter free and flattened beams. Phys Med. 2014 Jun;30(4):503-508. Pubmedid: 24662096.
  • Ahmed KA, Correa CR, Dilling TJ, Rao NG, Shridhar R, Trotti AM, Wilder RB, Caudell JJ. Altered fractionation schedules in radiation treatment: a review. Semin Oncol. 2014 Dec;41(6):730-750. Pubmedid: 25499633.
  • Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014 Dec;32(35):3930-3938. Pubmedid: 25267748. Pmcid: PMC4251957.
  • Trotti A, Zhang Q, Bentzen SM, Emami B, Hammond ME, Jones CU, Morrison WH, Sagar SM, Ridge JA, Fu KK, Ang KK. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys. 2014 Aug;89(5):958-963. Pubmedid: 25035199. Pmcid: PMC4709016.
  • Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014 Aug;50(8):765-769. Pubmedid: 24954065. Pmcid: PMC4593395.
  • Strom T, Trotti AM, Kish J, Rao NG, McCaffrey J, Padhya TA, Lin HY, Fulp W, Caudell JJ. Risk factors for percutaneous endoscopic gastrostomy tube placement during chemoradiotherapy for oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1242-1246. Pubmedid: 24136493.
  • Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar;31(7):845-852. Pubmedid: 23182993. Pmcid: PMC3577950.
  • May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Dec;35(12):1796-1800. Pubmedid: 23468387.
  • Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf G, Worden F. Mucosal melanoma of the head and neck. J Natl Compr Canc Netw. 2012 Mar;10(3):320-338. Pubmedid: 22393194.
  • Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012 Jun;30(17):2102-2111. Pubmedid: 22565003. Pmcid: PMC3397696.
  • Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH, Ang KK. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011 Oct;81(2):331-338. Pubmedid: 20732768. Pmcid: PMC2992592.
  • Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med. 2011 Mar;1(1):110-122. Pubmedid: 24073038. Pmcid: PMC3717706.
  • Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. J Natl Compr Canc Netw. 2011 Jun;9(6):596-650. Pubmedid: 21636536.
  • Rao NG, Yu HH, Trotti A, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan;20(1):115-131. Pubmedid: 21111962.
  • Trotti A, Eisbruch A. Reducing xerostomia through advanced technology. Lancet Oncol. 2011 Feb;12(2):110-111. Pubmedid: 21277541.
  • Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr;29(10):1326-1334. Pubmedid: 21357786. Pmcid: PMC3084000.
  • Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010 Jun;28(18):2996-3001. Pubmedid: 20479390.
  • Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun;28(18):2989-2995. Pubmedid: 20479425.
  • Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010 Apr;18(4):509-522. Pubmedid: 20145956.
  • Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep;27(26):4281-4286. Pubmedid: 19667273. Pmcid: PMC2744270.
  • Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009 Oct;38(4):522-532. Pubmedid: 19608377.
  • Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct;27(28):4727-4732. Pubmedid: 19720915. Pmcid: PMC2754914.
  • Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Martin Kast W, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Dansky Ullmann C. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422. Pubmedid: 19787782.
  • Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov;75(3):725-733. Pubmedid: 19362781.
  • Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.
  • Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.
  • Hensley M, Hagerty K, Kewalramani T, Green D, Meropol N, Wasserman T, Cohen G, Emami B, Gradishar W, Mitchell R, Thigpen J, Trotti A, von HoffD, Schuchter L. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009 Jan;27(1):127-145. Pubmedid: 19018081.
  • Forastiere AA, Trotti AM. Searching for less toxic larynx preservation: a need for common definitions and metrics. J Natl Cancer Inst. 2009 Feb;101(3):129-131. Pubmedid: 19176460.
  • Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.
  • Trotti A, Pajak TF, Ridge JA. Treatment of head and neck cancer. N Engl J Med. 2008 Mar;358(10):1076. Pubmedid: 18326079.
  • Machtay M, Moughan J, Trotti A, Garden A, Weber R, Cooper J, Forastiere A, Ang K. Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. J Clin Oncol. 2008 Jul;26(21):3582-3589. Pubmedid: 18559875.
  • Bensinger W, Schubert M, Ang K, Brizel D, Brown E, Eilers J, Elting L, Mittal B, Schattner M, Spielberger R, Treister N, Trotti AM 3rd. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008 Jan;6:S1-S21. Pubmedid: 18289497.
  • Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1351-1355. Pubmedid: 18640496. Pmcid: PMC2582390.
  • Davidson SE, Trotti A, Ataman OU, Seong J, Lau FN, da Motta NW, Jeremic B. Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys. 2007 Nov;69(4):1218-1221. Pubmedid: 17689027.
  • Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007 Nov;25(32):5121-5127. Pubmedid: 17991931.
  • Trotti A, Pajak T, Gwede C, Paulus R, Cooper J, Forastiere A, Ridge J, Watkins-Bruner D, Garden A, Ang K, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-624. Pubmedid: 17543584.
  • Calvin D, Hammond M, Pajak T, Trotti A, Meredith R, Rotman M, Jones C, Byhardt R, Demas W, Ang K, Fu K. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug;30(4):406-419. Pubmedid: 17762442.
  • Forastiere A, Trotti A, Pfister D, Grandis J. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun;24(17):2603-2605. Pubmedid: 16763271.
  • Chen Y, Trotti A, Coleman C, Machtay M, Mirimanoff R, Hay J, O'brien P, El-Gueddari B, Salvajoli J, Jeremic B. Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys. 2006 Apr;64(5):1442-1451. Pubmedid: 16414207.
  • Wood G, Casey L, Trotti A. Skin changes. Cancer Treat Res. 2006;128:171-181. Pubmedid: 16335018.
  • Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May;23(13):3008-3015. Pubmedid: 15860857.
  • Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments?. Jama. 2005 Feb;293(8):970-978. Pubmedid: 15728168. Pmcid: PMC1779758.
  • Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):674-681. Pubmedid: 14967419.
  • Trotti A, Bentzen S. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19-22. Pubmedid: 14657230.
  • Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov;349(22):2091-2098. Pubmedid: 14645636.
  • Hammond E, Berkey BA, Fu KK, Trotti A, Meredith RF, Jones CU, Byhardt R, Horwitz EM, Ang KK. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003. Int J Radiat Oncol Biol Phys. 2003 Nov;57(3):683-692. Pubmedid: 14529772.
  • Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C, Komaroff E, Nalysnyk L, Zilberberg M. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253-262. Pubmedid: 12742264.
  • Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. Pubmedid: 12903007.
  • Rose-Ped A, Bellm L, Epstein J, Trotti A, Gwede C, Fuch H. Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs. 2002 Dec;25(6):461-467. Pubmedid: 12464838.
  • Gwede C, Johnson D, Daniels S, Trotti A. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag. 2002;11(2):15-21. Pubmedid: 11989815.
  • Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol. 2002;12(1):1-3. Pubmedid: 11917276.
  • Kim C, Yeatman T, Coppola D, Trotti A, Williams B, Barthel J, Dinwoodie W, Karl R, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001 Sep;234(3):352-358. Pubmedid: 11524588. Pmcid: PMC1422026.
  • Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1-12. Pubmedid: 10758302.
  • Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T, Garden A, Ridge J, Cooper J, Ang K. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation to two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7-16. Pubmedid: 10924966.
  • Smith D, Messina J, Perrott R, Berman C, Reintgen D, Cruse C, Glass F, DeConti R, Trotti A, Fenske N. Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control. 2000;7(1):72-83. Pubmedid: 10740663.
  • Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormic B, Morris M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47. Pubmedid: 10758303.
  • Herskovic A, Scott C, Demas W, Gaspar L, Trotti A. Accelerated hyperfractionation for bronchogenic cancer: Radiation Therapy Oncology Group 9205. Am J Clin Oncol. 2000;23(2):207-212. Pubmedid: 10776986.
  • Flood W, Lee D, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Rad Oncol. 1999 Apr;9(2 Suppl 1):64-69. Pubmedid: 10210542.
  • Trotti, III A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck. 1998 Mar;20(2):119-123. Pubmedid: 9484942.
  • Sekharam M, Trotti, III A, Cunnick J, Wu J. Suppression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998 Apr;149(2):210-216. Pubmedid: 9571990.
  • Johnson D, Roberts C, Trotti, III A, Greenberg H. Professional satisfaction among radiation therapists: a regional survey. Radiation Therapist. 1998;7(1):103-110.
  • Trotti A, Johnson D, Gwede C, Casey L, Sauder B, Cantor A. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys. 1998;42(2):257-261. Pubmedid: 9788402.
  • Trotti, III A. Toxicity antagonists in cancer therapy. Curr Opin Oncol. 1997;9:569-578. Pubmedid: 9370079.
  • Futran N, Trotti, III A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Lancet. 1997;107(3):391-395. Pubmedid: 9121320.
  • Balducci L, Trotti, III A. Organ preservation: an effective and safe form of cancer treatment. Clin Geriatr Med. 1997;13(1):185-201. Pubmedid: 8995107.
  • Cruse C, Reintgen D, Glass F, Messina J, Trotti, III A, DeConti R. Clinical practice guidelines: neuroendocrine tumors of the skin. Cancer Control. 1997;4:258-260. Pubmedid: noPMID.
  • Vaidynathan M, Clarke L, Velthuizen R, Phuphanich S, Bensaid A, Hall L, Bezdek J, Greenberg H, Trotti, III A, Silbiger M. Comparison of supervised MRI segmentation methods for tumor volume determination during therapy. Magn Reson Imaging. 1995;13(5):719-728. Pubmedid: 8569446.
  • Endicott J, Trotti III A. Organ preservation in patients with head and neck cancer. Cancer Control. 1994;1(1):13-19.
  • Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey. Blood. 1993;82:2245-2245.
  • Trotti III A, Klotch D, Endicott J, Ridley M, Greenberg H. A prospective trial of accelerated radiotherapy in the postoperative treatment of high risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1993;26(1):13-21. Pubmedid: 8482619.
  • Trotti III A, Peters L. The role of radiotherapy in the primary management of muscosal melanoma. Ann Plast Surg. 1992;28(1):39-44.
  • Trotti III A, Peters L. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol. 1992;9(3):246-250.
  • Johnson D, Casey L, Gwede C, Friedland J, Trotti, III A. 1996;850-851.